Physician profile
Mark A Ward
NPI 1235635921
$1,318.63
in general payments reported to CMS, 2019-2025
16 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.89 · 2021: $38.65 · 2022: $189 · 2023: $558 · 2024: $351 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $331.26 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Medtronic, INC. | $282.21 | 2023 | Ligasure |
| Ambu INC. | $158.35 | 2022 | |
| Davol INC. | $128.89 | 2025 | Phasix Mesh |
| Intuitive Surgical, INC. | $119.73 | 2023 | Da Vinci Surgical System |
| Baxter Healthcare | $62.41 | 2021-2023 | Tisseel |
| Aroa Biosurgery Incorporated | $54.54 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2022-2023 | Imfinzi |
| Abbvie INC. | $23.76 | 2023 | Alloderm |
| Polynovo North America LLC | $20.85 | 2023 | |
| Trevena, INC. | $20.76 | 2023 | Olinvyk |
| Takeda Pharmaceuticals U.S.A., INC. | $20.35 | 2023 | Gattex |
| Shionogi INC | $18.29 | 2023 | Fetroja |
| Csl Behring | $17.89 | 2019 | |
| Kci USA, INC. | $16.48 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.